Gsk Pharma

GSK Pharma shares fall 3% as revenue misses expectations; Q2 breakdown here

GSK Pharma shares fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current financial year

GSK Pharma gains depend on new launches, traction in base business

The Q1 was impacted by sluggish show of the base business and supply disruption, resulting in brokerages cutting their earnings estimates

GSK plans $30 billion US investment as pharma tariff threat looms

The company said its new facilities will bridge R&D and manufacturing across both the US and UK, strengthening the two countries' leadership in life sciences

GSK enters into oncology segment; launches therapies for gynae cancers

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore for the June quarter. The drug firm had reported a net profit of Rs 249 crore for the June quarter of the last fiscal. Total income declined marginally to Rs 849 crore for the first quarter as compared with Rs 850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet nee

Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK

Fire disrupts production at GSK Pharma's contract manufacturing site

GSK Pharmaceuticals has reported a fire at one of its contract sites, causing temporary disruption; the company is assessing the impact and working to restore operations

Here's why GSK Pharma share price was buzzing in trade on Wednesday, May 14

The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results.

GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches including Zejula and Jemperli on track

GSK Pharma surges 10%, stock hits all-time high; Buy, sell or hold?

Thus far in the calendar year 2025, the stock price of GSK Pharma has zoomed 40 per cent, as against 1.8 per cent rise in BSE Sensex.

Trend turns favourable for GlaxoSmithKline Pharma, key levels to track

GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.

US FDA approves GSK's 'Blujepa' for treating UTIs in women and girls

The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the standard-of-care medication introduced in the 1950s

GSK Pharma hits 3-month high in weak market; surges 31% in 7 days

GSK Pharma share price: The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December quarter

GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday's intraday trade

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market

Valuations may temper gains for GlaxoSmithKline Pharma despite strong Q1

The brokerage has estimated a 9 per cent earnings growth over FY24-26 for GSK Pharma

GSK Pharma Q1 FY25 results: Net profit rises 37%, revenue up 6.9%

GSK Pharma's stocks were up by 2.49 per cent, ending the day's trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)

New product launches may continue to fuel GSK Pharma's robust growth

GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding

GSK seeks to appeal Delaware ruling allowing Zantac cases to go forward

The companies, which all sold Zantac at different times, argue that Medinilla should have granted their motion to block plaintiffs from presenting expert testimony that Zantac causes cancer

GSK Pharma Q4 results: Profit rises 45% on growth in NLEM drugs, vaccines

The board has recommended a dividend of Rs 32 per equity share on face value of Rs 10 each for the year ended 31 March 2024, subject to approval of members at 99th Annual General Meeting